Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes

 Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes

Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes

Shots:

  • Thermo Fisher and NX Prenatal enter into a collaboration to develop proteomics assays by combining NX Prenatal’s NeXosome platform with Thermo Fisher’s LC-MS instrumentation for monitoring the maternal & fetal health and evaluating the risk of complications
  • The focus of the collaboration is to provide a diagnostic solution to both clinical and medical professionals by evaluating maternal and fetal biomarkers during pregnancy and to assess adverse outcomes including preterm birth and preeclampsia for improving health
  • NX Prenatal’s NeXosome technology harvest microparticles (exosomes) from the mother’s blood, maintaining the balance between mother & fetus during the pregnancy

Click here to read full press release/ article | Ref: Thermo Fisher | Image: Evaluating Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post